476P Meta-analysis of randomised clinical trials comparing erlotinib alone with erlotinib plus chemotherapy in patients with advanced non–small cell lung cancer

Abstract

Background: To determine whether the use of Erlotinib plus chemotherapy is more effective than the use of Erlotinib alone in patients with advanced non-small cell lung cancer. Methods: A computer-based search was performed. Randomised trials comparing Erlotinib alone with Erlotinib plus chemotherapy as therapy for advanced non-small cell lung cancer were included in this meta-analysis. The primary outcome of interest for our analysis was survival (progression-free survival, and overall survival). Results: Four trials with 485 patients were eligible for this meta-analysis. Our pooled results suggest that Erlotinib plus chemotherapy is associated with a significant advantage in PFS (HR=0.51; 95% CI=0.32-0.81, p=0.004), but not in OS (HR=1.03; 95% CI=0.73-1.32, p=0.92). Conclusions: Our analysis indicated that Erlotinib plus chemotherapy could improve the PFS compared to Erlotinib alone as therapy for patients with advanced non-small cell lung cancer. Further study is needed to determine whether Erlotinib plus chemotherapy can produce clinical benefits in selected genetic or molecular subgroups of advanced non-small cell lung cancer.